Clinical Trial Update: Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the immunomodulatory effects of silymarin in patients with beta-thalassemia major. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Shiraz University of Medical Sciences | Conditions: Immune Abnormalities | Phase 1 | Status: COMPLETED